MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Sharon Elad, Karis Kin Fong Cheng, Rajesh V Lalla, Noam Yarom, Catherine Hong, Richard M Logan, Joanne Bowen, Rachel Gibson, Deborah P Saunders, Yehuda Zadik, Anura Ariyawardana, Maria Elvira Correa, Vinisha Ranna, Paolo Bossi, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO), Praveen Arany, Abdul Rahman Al-Azri, Nicole Blijlevens, Allan Hovan, Eduardo Fregnani, Janet Fulton, Luiz Alcino Gueiros, Tanya Rouleau, Janet K Coller, Noor Al-Dasooqi, Hannah Wardill, Suzanne Ameringer, Héliton Spindola Antunes, Emma H Bateman, Kivanc Bektas, René-Jean Bensadoun, K Ten Bohmer, Norman Brito-Dellan, Daniel Castillo, Karen Chiang, Charlotte de Mooij, June Eilers, Joel Epstein, Dimitra Galiti, Jane M Fall-Dickson, Margherita Gobbo, Hanan Issa Hazboun, Siri Beier Jensen, Jorgen Johansen, Jamie Joy, K Joy, Abhishek Kandwal, Tomoko Kataoka, Dorothy Keefe, Charles L Loprinzi, Rachel Lubart, Anna Skripnik Lucas, Alessandra Majorana, Bronwen Mayo, Charlotte de Mooij, Takehiko Mori, Raj G Nair, Narmin Nasr, Ourania Nicolatou-Galitis, Giulia Ottaviani, Cesar Migliorati, Monica Pentenero, Lorraine Porcello, Douglas Peterson, Carin Potting, Judith Raber-Durlacher, Ysabella Z A van Sebille, Yoshihiko Soga, Stephen Sonis, Andrea M Stringer, Daniel Thorpe, Vanessa Tilly, Wim Tissing, Juan J Toro, Nathaniel Simon Treister, Anusha Vaddi, Dianna Weikel, Marianne van de Wetering, Eyal Zur, Sharon Elad, Karis Kin Fong Cheng, Rajesh V Lalla, Noam Yarom, Catherine Hong, Richard M Logan, Joanne Bowen, Rachel Gibson, Deborah P Saunders, Yehuda Zadik, Anura Ariyawardana, Maria Elvira Correa, Vinisha Ranna, Paolo Bossi, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO), Praveen Arany, Abdul Rahman Al-Azri, Nicole Blijlevens, Allan Hovan, Eduardo Fregnani, Janet Fulton, Luiz Alcino Gueiros, Tanya Rouleau, Janet K Coller, Noor Al-Dasooqi, Hannah Wardill, Suzanne Ameringer, Héliton Spindola Antunes, Emma H Bateman, Kivanc Bektas, René-Jean Bensadoun, K Ten Bohmer, Norman Brito-Dellan, Daniel Castillo, Karen Chiang, Charlotte de Mooij, June Eilers, Joel Epstein, Dimitra Galiti, Jane M Fall-Dickson, Margherita Gobbo, Hanan Issa Hazboun, Siri Beier Jensen, Jorgen Johansen, Jamie Joy, K Joy, Abhishek Kandwal, Tomoko Kataoka, Dorothy Keefe, Charles L Loprinzi, Rachel Lubart, Anna Skripnik Lucas, Alessandra Majorana, Bronwen Mayo, Charlotte de Mooij, Takehiko Mori, Raj G Nair, Narmin Nasr, Ourania Nicolatou-Galitis, Giulia Ottaviani, Cesar Migliorati, Monica Pentenero, Lorraine Porcello, Douglas Peterson, Carin Potting, Judith Raber-Durlacher, Ysabella Z A van Sebille, Yoshihiko Soga, Stephen Sonis, Andrea M Stringer, Daniel Thorpe, Vanessa Tilly, Wim Tissing, Juan J Toro, Nathaniel Simon Treister, Anusha Vaddi, Dianna Weikel, Marianne van de Wetering, Eyal Zur

Abstract

Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis.

Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.

Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions.

Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.

Keywords: Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO); cancer; gastrointestinal; guidelines; mucositis; oral.

Conflict of interest statement

According to Multinational Association of Supportive Care in Cancer (MASCC) guidelines policy, employees of commercial entities were not eligible to serve on this MASCC Guidelines Panel. Sharon Elad reports consultation fees from Falk Pharma, outside the submitted work. Rajesh V. Lalla reports institutional research support from Novartis, Oragenics, and Sucampo Pharma, outside the submitted work; grants and personal fees from Galera Therapeutics, outside the submitted work; personal fees from Alira Health, Colgate Oral Pharmaceuticals, Eagle Pharma, Enlivity, Ingalfarma SA, Meiji Seika Pharma, Monopar Therapeutics, Mundipharma, and Sucampo Pharma, outside the submitted work; stock ownership in Logic Biosciences; and has a patent pending (WO 2019/217536 A2; University of Connecticut, applicant). Deborah P. Saunders reports institutional research support from Galera Therapeutics. Paolo Bossi reports personal fees from Merck Serono, Roche, Sanofi, Merck Sharp & Dohme, Sun Pharma, AstraZeneca, Kyowa Hakko Kyrin, AstraZeneca, Bristol‐Myers Squibb, Helsinn, and Glaxo‐Smith‐Kline, outside the submitted work. The remaining authors made no disclosures.

© 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

References

    1. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem‐cell transplantation. J Clin Oncol. 2001;19:2201‐2205.
    1. Vera‐Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem‐cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007;15:491‐496.
    1. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy‐induced mucositis. Cancer. 2003;98:1531‐1539.
    1. Keefe DM, Gibson RJ, Hauer‐Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs. 2004;20:38‐47.
    1. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy‐induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026‐2046.
    1. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820‐831.
    1. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO Clinical Practice Guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453‐1461.
    1. Ranna V, Cheng KKF, Castillo DA, et al. Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods. Support Care Cancer. 2019;27:3933‐3948.
    1. Somerfield MR, McCrae RR. Stress and coping research. Methodological challenges, theoretical advances, and clinical applications. Am Psychol. 2000;55:620‐625.
    1. Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol. 1996;49:749‐754.
    1. Hong CHL, Gueiros LA, Fulton JS, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27:3949‐3967.
    1. Ariyawardana A, Cheng KKF, Kandwal A, et al. Systematic review of anti‐inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27:3985‐3995.
    1. Zadik Y, Arany PR, Fregnani ER, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27:3969‐3983.
    1. Bowen JM, Gibson RJ, Coller JK, et al. Systematic review of agents for the management of cancer treatment‐related gastrointestinal mucositis and clinical practice guidelines. Support Care Cancer. 2019;27:4011‐4022.
    1. Yarom N, Hovan A, Bossi P, et al. Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines‐part 1: vitamins, minerals, and nutritional supplements. Support Care Cancer. 2019;27:3997‐4010.
    1. Yarom N, Hovan A, Bossi P, et al. Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines—part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. Support Care Cancer. 2020;28:2457‐2472.
    1. Saunders DP, Rouleau T, Cheng K, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020;28:2473‐2484.
    1. Correa MEP, Cheng KKF, Chiang K, et al. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020;28:2449‐2456.
    1. Diaz‐Sanchez RM, Pachon‐Ibanez J, Marin‐Conde F, Rodriguez‐Caballero A, Gutierrez‐Perez JL, Torres‐Lagares D. Double‐blind, randomized pilot study of bioadhesive chlorhexidine gel in the prevention and treatment of mucositis induced by chemoradiotherapy of head and neck cancer. Med Oral Patol Oral Cir Bucal. 2015;20:e378‐e385.
    1. Roopashri G, Jayanthi K, Guruprasad R. Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: a drug trial. Contemp Clin Dent. 2011;2:8‐12.
    1. Low‐Level Light Therapy. Accessed May 19, 2020.
    1. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:333‐341.
    1. Sonis ST, Hashemi S, Epstein JB, Nair RG, Raber‐Durlacher JE. Could the biological robustness of low level laser therapy (photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol. 2016;54:7‐14.
    1. Antunes HS, Herchenhorn D, Small IA, et al. Long‐term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low‐level laser therapy (LLLT) to prevent oral mucositis. Oral Oncol. 2017;71:11‐15.
    1. Brandao TB, Morais‐Faria K, Ribeiro ACP, et al. Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses. Support Care Cancer. 2018;26:2417‐2423.
    1. de Pauli Paglioni M, Araujo ALD, Arboleda LPA, et al. Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities. A systematic review. Oral Oncol. 2019;93:21‐28.
    1. Logan RM, Al‐Azri AR, Bossi P, et al. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020;28:2485‐2498.
    1. European Medicines Agency (EMA) . Kepivance. Accessed July 28, 2019.
    1. Uderzo C, Rebora P, Marrocco E, et al. Glutamine‐enriched nutrition does not reduce mucosal morbidity or complications after stem‐cell transplantation for childhood malignancies: a prospective randomized study. Transplantation. 2011;91:1321‐1325.
    1. Pytlik R, Benes P, Patorkova M, et al. Standardized parenteral alanyl‐glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double‐blind, placebo controlled study. Bone Marrow Transplant. 2002;30:953‐961.
    1. Yarom N, Ariyawardana A, Hovan A, et al. Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3209‐3221.
    1. Bowen J, Al‐Dasooqi N, Bossi P, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019;27:4023‐4033.
    1. Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016;24:4825‐4830.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다